See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Diabetes Investing

David Kliff

Diabetes Investing

Insulin (Humalog) Pen Demo

J. Scott MacGregor

Insulin (Humalog) Pen Demo

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Novo Nordisk

Page 5
Pump and Sensor Combo Beats MDI Decisively in Medtronic’s STAR 3 Study
Jul 13, 2010 | 
A massive study involving 485 people with type 1 diabetes at 30 locations across North America shows that the combination of an insulin pump and a continuous glucose monitor helps patients achieve significantly lower A1c levels than multiple daily insulin injections.
More from ACCORD
Jul 2, 2010 | 
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.
DHTV
Popular
Top Rated

Related Community Videos on Diabetes Health TV

Diabetes Investing

David Kliff

Diabetes Investing

Insulin (Humalog) Pen Demo

J. Scott MacGregor

Insulin (Humalog) Pen Demo

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease
Apr 4, 2010 | 
Novo Nordisk, a global healthcare company and leader in diabetes care, announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
FDA Hedges Approval of Long-Acting Byetta, Asks Amylin for More Information
Mar 29, 2010 | 
The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta.  The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.
Starting Treatment Early Doubles Chance of Success for People with Diabetes
Mar 12, 2010 | 
The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.
FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.
Feb 27, 2010 | 
Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.
Diabetes and Pre-Diabetes Cost the U.S. $218 Billion in 2007: En Route to $336 Billion by 2034
Feb 3, 2010 | 
A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.